PURPOSE: The principal goal of treatment of laryngeal cancer is to eliminate a tumour while preserving laryngeal function with radio(chemo)therapy being the mainstay of treatment. The aim of this report is to present the influence of comorbidities and lifestyle factors on treatment outcomes in our cohort of patients. METHODS: During the period 2009-2018, curative radio(chemo)therapy for laryngeal cancer was performed on 189 patients. RESULTS: The median OS was 50.8 months, with a mean PFS of 96.5 months, mean LC of 101.4 months and a median follow-up of 38.1 months. Acute and late treatment toxicity grade 3-4 was observed in 39.2% patients and 10.1% patients, respectively. A significant effect on overall survival was confirmed for the baseline PS (performance status), severity of weight loss, baseline haemoglobin values, history of alcohol abuse, marital status and comorbidities according to the Charlson Comorbidity Index, as well as the ACE-27 and ASA scores. CONCLUSIONS: In our cohort of patients treated with radio(chemo)therapy for laryngeal cancer, we found good therapeutic results and an acceptable side-effect profile. Statistically significant predictors of overall survival were the baseline PS, weight loss, anaemia, associated comorbidities, history of alcohol abuse and marital status.

Department of Oncology 1st Faculty of Medicine Charles University and Thomayer University Hospital Prague Czech Republic

Institute of Radiation Oncology 1st Faculty of Medicine Charles University and Bulovka University Hospital Budinova 67 2 18081 Prague Czech Republic

Military University Hospital Prague Czech Republic

National Radiation Protection Institute Prague Czech Republic

Zobrazit více v PubMed

Steuer CE, El-Deiry M, Parks JR, Higgins KA, Saba NF. An update on larynx cancer. CA Cancer J Clin. 2017;67(1):31–50. doi: 10.3322/caac.21386. PubMed DOI

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. doi: 10.3322/caac.21332. PubMed DOI

Dusek L, Muzik J, Kubasek M et al Epidemiology of malignant tumours in the Czech Republic. http://www.svod.cz. Accessed 17 Oct 2022

Vosmik M, Klozar J. Total laryngectomy or larynx-preservation strategy? Current treatment approaches. Onkologie. 2021;15(2):63–66. doi: 10.36290/xon.2021.012. DOI

Pala M. Treatment of laryngeal carcinoma. Onkologie. 2016;10(3):138–141. doi: 10.36290/xon.2016.030. DOI

American Society of Clinical Oncology. Pfister DG, Laurie SA, Weinstein GS, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol. 2006;24(22):3693–3704. doi: 10.1200/JCO.2006.07.4559. PubMed DOI

Forastiere AA, Ismaila N, Lewin JS, et al. Use of larynx-preservation strategies in the treatment of laryngeal cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36(11):1143–1169. doi: 10.1200/JCO.2017.75.7385. PubMed DOI

National Comprehensive Cancer Network (NCCN) (2022) Head and neck cancers, version 2. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (Created 26 Apr 2022). Accessed 17 Oct 2022

Obid R, Redlich M, Tomeh C. The treatment of laryngeal cancer. Oral Maxillofac Surg Clin North Am. 2019;31(1):1–11. doi: 10.1016/j.coms.2018.09.001. PubMed DOI

Shelan M, Anschuetz L, Schubert AD, Bojaxhiu B, Dal Pra A, Behrensmeier F, Aebersold DM, Giger R, Elicin O. T1-2 glottic cancer treated with radiotherapy and/or surgery. Strahlenther Onkol. 2017;193(12):995–1004. doi: 10.1007/s00066-017-1139-4. PubMed DOI

Mucha-Małecka A, Chrostowska A, Urbanek K, Małecki K. Prognostic factors in patients with T1 glottic cancer treated with radiotherapy. Strahlenther Onkol. 2019;195(9):792–804. doi: 10.1007/s00066-019-01481-2. PubMed DOI PMC

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8. PubMed DOI

Charlson Comorbidity Index (CCI)—The calculator. https://www.mdcalc.com. Accessed 17 Oct 2022

Piccirillo JF, Creech CM, Zequeira R, Anderson S, Johnston AS. Inclusion of comorbidity into oncology data registries. J Reg Manag. 1999;26:66–70.

Hurwitz EE, Simon M, Vinta SR, Zehm CF, Shabot SM, Minhajuddin A, Abouleish AE. Adding examples to the ASA-physical status classification improves correct assignment to patients. Anesthesiology. 2017;126(4):614–622. doi: 10.1097/ALN.0000000000001541. PubMed DOI

Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) Int J Radiat Oncol Biol Phys. 1995;31(5):1341–1346. doi: 10.1016/0360-3016(95)00060-C. PubMed DOI

Multidisciplinary Larynx Cancer Working Group. Mulcahy CF, Mohamed A, Kanwar A, et al. Age-adjusted comorbidity and survival in locally advanced laryngeal cancer. Head Neck. 2018;40(9):2060–2069. doi: 10.1002/hed.25200. PubMed DOI PMC

Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope. 2000;110(4):593–602. doi: 10.1097/00005537-200004000-00011. PubMed DOI

Paleri V, Wight RG, Davies GR. Impact of comorbidity on the outcome of laryngeal squamous cancer. Head Neck. 2003;25(12):1019–1026. doi: 10.1002/hed.10333. PubMed DOI

Pala M, Novakova P, Pechacova Z, Vesela L, Vrana A, Sukova J, Holeckova P, Drbohlavova T, Podlesak T, Petruzelka L. Long-term results of radio(chemo)therapy in metastatic carcinoma to cervical lymph nodes from an unknown primary. Adult Comorbidity Evaluation 27 score as a predictor of survival. Strahlenther Onkol. 2022 doi: 10.1007/s00066-022-01983-6. PubMed DOI

Department of Veterans Affairs Laryngeal Cancer Study Group. Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, Laramore GE, Endicott JW, McClatchey K, Henderson WG. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324(24):1685–1690. doi: 10.1056/NEJM199106133242402. PubMed DOI

Rutkowski T, Suwinski R, Idasiak A. The prognostic value of hemoglobin concentration in postoperative radiotherapy of 835 patients with laryngeal cancer. Int J Radiat Oncol Biol Phys. 2007;69(4):1018–1023. doi: 10.1016/j.ijrobp.2007.04.064. PubMed DOI

Wagner W, Hermann R, Hartlapp J, Esser E, Christoph B, Müller MK, Krech R, Koch O. Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery. Strahlenther Onkol. 2000;176(2):73–80. doi: 10.1007/pl00002331. PubMed DOI

Lohynska R, Jirkovska M, Malinova B, Novakova-Jiresova A, Pechacova Z, Kratka Z. Tumour volume and radiotherapy prolongation in locally advanced head and neck cancer patients treated with radical IMRT. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021 doi: 10.5507/bp.2021.047. PubMed DOI

Lohynska R, Jirkovska M, Novakova-Jiresova A, Kratka Z, Malinova B. Determining priority risk groups for compensation of treatment breaks in radical radiotherapy in patients with locally advanced head and neck cancer. J BUON2. 2021;26(3):792–801. PubMed